daliresp
(roflumilast)AstraZeneca Pharmaceuticals LP
Usage: DALIRESP® is indicated for reducing the risk of COPD exacerbations in patients with severe COPD linked to chronic bronchitis and a history of exacerbations. It is not a bronchodilator and should not be used for acute bronchospasm relief. The initial dose is 250 mcg for the first four weeks only.